Telephone: +44 207-882-8236; Fax: +44 207-882-8252
Translational and Clinical Research
Mesenchymal Stromal Cells: Current Understanding and Clinical Status†
Version of Record online: 4 DEC 2009
Copyright © 2010 AlphaMed Press
Volume 28, Issue 3, pages 585–596, March 2010
How to Cite
Salem, H. K. and Thiemermann, C. (2010), Mesenchymal Stromal Cells: Current Understanding and Clinical Status. STEM CELLS, 28: 585–596. doi: 10.1002/stem.269
Author contributions: H.S.: Conception and design, collection and/or assembly of data, manuscript writing; C.T.: Final approval of manuscript.
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS December 4, 2009.
- Issue online: 24 MAR 2010
- Version of Record online: 4 DEC 2009
- Accepted manuscript online: 4 DEC 2009 12:00AM EST
- Manuscript Accepted: 25 NOV 2009
- Manuscript Received: 7 APR 2009
- William Harvey Research Foundation
- Stem cells;
- Mesenchymal stromal cells;
- T lymphocytes;
- Dentritic cells;
Multipotent mesenchymal stromal cells (MSCs) represent a rare heterogeneous subset of pluripotent stromal cells that can be isolated from many different adult tissues that exhibit the potential to give rise to cells of diverse lineages. Numerous studies have reported beneficial effects of MSCs in tissue repair and regeneration. After culture expansion and in vivo administration, MSCs home to and engraft to injured tissues and modulate the inflammatory response through synergistic downregulation of proinflammatory cytokines and upregulation of both prosurvival and antiinflammatory factors. In addition, MSCs possess remarkable immunosuppressive properties, suppressing T-cell, NK cell functions, and also modulating dentritic cell activities. Tremendous progress has been made in preclinical studies using MSCs, including the ability to use allogeneic cells, which has driven the application of MSCs toward the clinical setting. This review highlights our current understanding into the biology of MSCs with particular emphasis on the cardiovascular and renal applications, and provides a brief update on the clinical status of MSC-based therapy. STEM CELLS 2010;28:585–596